Condition: Cystic Fibrosis · Sponsor: ReCode Therapeutics
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
This description comes directly from the study's public registry record.
Priya Ryali, MBA · 650-629-7900 · clinicaltrials@recodetx.com
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of Arizona | Tucson, Arizona, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| UCSD | San Diego, California, United States | Recruiting |
| National Jewish Health | Denver, Colorado, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| New York Medical College | Valhalla, New York, United States | Recruiting |
| The University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06237335